CVS director Mike Mahoney, whose day job is CEO of Boston Scientific, bought 30,000 shares of the healthcare company.

Principal Securities Inc. grew its holdings in shares of CVS Health Co. (NYSE:CVS – Free Report) by 3.2% during the fourth ...

Extending its 23%-plus climb during 2024, the S&P 500 started 2025 off with a bang, rising 2.7% in January.

Despite a recent 45% rally, I maintain a 'Sell' view on CVS due to its underwhelming execution record and rising leverage ...

In the latest executive shakeup at CVS, the pharmacy giant has named a new president of its pharmacy benefit management ...

Argus raised the firm’s price target on CVS Health (CVS) to $77 from $68 and keeps a Buy rating on the shares. Despite an uneven performance ...

In a report released on February 14, Steven Silver from Argus Research maintained a Buy rating on CVS Health (CVS – Research Report). The ...

Earnings have fallen but are still strong enough to meet CVS Health's dividend commitment. Management expects adjusted ...

We recently compiled a list of the 10 Best Performing S&P 500 Stocks So Far in 2025. In this article, we are going to take a ...

New York Times Co.’s stock fell sharply on Wednesday as analysts questioned a sequential increase in the money the company spends to advertise its media properties. The New York Times NYT also ...

CVS Health exceeded Q4 sales estimates with $97.71B revenue. The company projects 2025 revenue above $134B and expects ...

CVS Health Corporation (NYSE:CVS) is a retailer that operates in four segments: health care benefits, health services, ...